Pfizer Inc. vs Abbvie Inc.
PFE vs ABBV — side-by-side comparison from reported financials. PFE leads 3, ABBV leads 8 of 11 comparable metrics.
Pfizer Inc.
PFE · Healthcare
$28.27+1.62%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | PFE | ABBV |
|---|---|---|
| Price | $28.27 | $276.43 |
| Market cap | $161B | $488B |
| Revenue (TTM) | $63.7B | $64.4B |
| Revenue growth | -14.8% | +1.8% |
| Net margin | 6.8% | 9.8% |
| Free cash flow | $11.0B | $18.2B |
| Net cash (debt) | ($51.6B) | ($56.2B) |
| 1-year price return | +12.0% | +19.8% |
| P/E | 37.2 | 77.4 |
| P/E vs own history (cheap-side %) | 4% | 23% |
| Dividend yield | 6.07% | 2.45% |
| Return on equity | 5% | 96% |
| Altman Z-score | 1.96 | 2.33 |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 75,000 | 57,000 |
Full résumé-style profiles: PFE CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.